116 related articles for article (PubMed ID: 1191326)
1. The metabolism of the anti-tumour agent 1(1-aziridinyl)- 2,4-dinitrobenzene (CB 1837).
Connors TA; Hickman JA; Jarman M; Melzack DH; Ross WC
Biochem Pharmacol; 1975 Sep; 24(18):1665-70. PubMed ID: 1191326
[No Abstract] [Full Text] [Related]
2. The metabolism of the anti-tumour agent 5-(1-aziridinyl)-2,4-dinitrobenzamide (CB 1954).
Jarman M; Melzack DH; Ross WC
Biochem Pharmacol; 1976 Nov; 25(22):2475-8. PubMed ID: 985569
[No Abstract] [Full Text] [Related]
3. [Metabolism of the antineoplastic agent N-pyrimidly-2N1, N2-di-(ethylene)-triamide phosphate (fosfemid)].
Safonova TS; Linberg LF; Presnova ZhF; Kuriatov NS; Chernov VA
Dokl Akad Nauk SSSR; 1974; 219(5):1271-2. PubMed ID: 4442341
[No Abstract] [Full Text] [Related]
4. CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cells.
Roberts JJ; Friedlos F; Knox RJ
Biochem Biophys Res Commun; 1986 Nov; 140(3):1073-8. PubMed ID: 3778483
[TBL] [Abstract][Full Text] [Related]
5. Structure activity relationships in a series of anti-neoplastic dinitrophenyl aziridines--protein binding studies.
Hickman JA
Biochem Pharmacol; 1974 Oct; 23(20):2833-8. PubMed ID: 4473986
[No Abstract] [Full Text] [Related]
6. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells.
Knox RJ; Friedlos F; Jarman M; Roberts JJ
Biochem Pharmacol; 1988 Dec; 37(24):4661-9. PubMed ID: 3202902
[TBL] [Abstract][Full Text] [Related]
7. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2).
Knox RJ; Boland MP; Friedlos F; Coles B; Southan C; Roberts JJ
Biochem Pharmacol; 1988 Dec; 37(24):4671-7. PubMed ID: 3144286
[TBL] [Abstract][Full Text] [Related]
8. The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT).
Knox RJ; Friedlos F; Boland MP
Cancer Metastasis Rev; 1993 Jun; 12(2):195-212. PubMed ID: 8375021
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of ribonucleotide reductase by the monofunctional alkylating agent 5(1-aziridinyl)-2,4-dinitrobenzamide (CB 1954).
Tisdale MJ; Habberfield AD
Biochem Pharmacol; 1980 Oct; 29(20):2845-53. PubMed ID: 7002161
[No Abstract] [Full Text] [Related]
10. Studies on the mechanism of action of 5-aziridinyl-2,4-dinitrobenzamide (CB 1954), a selective inhibitor of the Walker tumour.
Connors TA; Melzack DH
Int J Cancer; 1971 Jan; 7(1):86-92. PubMed ID: 5546147
[No Abstract] [Full Text] [Related]
11. Effects of ascorbic acid on biologically obtained diaziquone free radicals.
Gutierrez PL; Egorin MJ; Davis TA; Bachur NR
Biochem Pharmacol; 1985 Jul; 34(13):2394-7. PubMed ID: 2990485
[No Abstract] [Full Text] [Related]
12. [Study of the pharmacokinetics of phosphemide in rats with the use of physico-chemical methods].
Safonova TS; Presnova ZhF; Linberg LF; Chernov VA; Kuriatov NS
Farmakol Toksikol; 1975; 38(4):491-4. PubMed ID: 1213145
[TBL] [Abstract][Full Text] [Related]
13. Protection against the effects of the antitumour agent CB 1954 by certain imidazoles and related compounds.
Hickman JA; Melzack DH
Biochem Pharmacol; 1975 Nov; 24(21):1947-52. PubMed ID: 1212244
[No Abstract] [Full Text] [Related]
14. [Quantitative aspects of the relationship of the antitumor activity and toxicity of diaziridinyl-sym. triazines to their physicochemical properties].
Ivin BA; Filov VA; Kraĭz BO; Belogorodskiĭ VV; Maliugina LL
Vopr Onkol; 1979; 25(7):71-5. PubMed ID: 483685
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and electron spin resonance study of spin-labelled compounds related to tumour-growth inhibitory nitroarylaziridines.
Dodd NJ; Harcus RG; Preston PN
Z Naturforsch C Biosci; 1976; 31(5-6):328-30. PubMed ID: 183409
[TBL] [Abstract][Full Text] [Related]
16. Biochemical activation of AZQ [3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone] to its free radical species.
Gutierrez PL; Friedman RD; Bachur NR
Cancer Treat Rep; 1982 Feb; 66(2):339-42. PubMed ID: 6275990
[TBL] [Abstract][Full Text] [Related]
17. Proceedings: Protection against the cytotoxic aziridine CB1954 by an arylimidazole with anti-inflammatory activity.
Hickman JA; Melzack DH
Br J Cancer; 1975 Aug; 32(2):244. PubMed ID: 1212363
[No Abstract] [Full Text] [Related]
18. [Antitumor activity and pharmacological properties of furizil].
Stukov AN; Kraĭz BO; Aleksandrov VA; Ivin BA; Filov VA
Vopr Onkol; 1985; 31(5):52-4. PubMed ID: 4013130
[TBL] [Abstract][Full Text] [Related]
19. Isomer-dependent cytostatic activity of bis(1-aziridinyl)cyclophosphazenes.
van der Huizen AA; Wilting T; van de Grampel JC; Lelieveld P; van der Meer-Kalverkamp A; Lamberts HB; Mulder NH
J Med Chem; 1986 Aug; 29(8):1341-5. PubMed ID: 3735303
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic activity and fragmentation of aziridines in microsomes.
Hata Y; Watanabe M; Shiratori O; Takase S
Biochem Biophys Res Commun; 1978 Feb; 80(4):911-6. PubMed ID: 637875
[No Abstract] [Full Text] [Related]
[Next] [New Search]
